콘텐츠로 건너뛰기
주식/증권 📈 긍정적

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

요약

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.